Great Valley Advisor Group Inc. Has $2.75 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Great Valley Advisor Group Inc. cut its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 12.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 103,766 shares of the biopharmaceutical company's stock after selling 15,357 shares during the quarter. Great Valley Advisor Group Inc.'s holdings in Pfizer were worth $2,753,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parsons Capital Management Inc. RI boosted its stake in Pfizer by 118.7% in the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after acquiring an additional 159,984 shares during the last quarter. Mcdonald Partners LLC boosted its position in shares of Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after purchasing an additional 9,963 shares in the last quarter. Bank of Jackson Hole Trust bought a new position in shares of Pfizer during the fourth quarter worth $264,000. Harvey Capital Management Inc. bought a new position in shares of Pfizer during the fourth quarter worth $544,000. Finally, ING Groep NV boosted its position in shares of Pfizer by 48.6% during the fourth quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company's stock worth $26,881,000 after purchasing an additional 331,403 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PFE. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Down 1.8%

PFE stock traded down $0.43 during midday trading on Wednesday, hitting $23.18. The company's stock had a trading volume of 36,659,825 shares, compared to its average volume of 41,097,811. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company's fifty day moving average price is $23.28 and its 200 day moving average price is $25.12. The stock has a market capitalization of $131.79 billion, a P/E ratio of 16.44, a PEG ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the business earned $0.82 EPS. The company's revenue was down 7.8% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.42%. Pfizer's dividend payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.